TG Therapeutics has built an elite business quality profile with 113% return on equity, 66% gross margins, and 70% revenue growth, but a complete 4-of-4 quarter earnings miss streak averaging -39.9% below consensus and 27% short interest create a fundamental tension between the operational quality of BRIUMVI and the company's ability to convert revenue into reported earnings.
Thesis pillars
- Exceptional Quality And Growth Metrics→Stable
- Briumvi Single Product Concentration↓Deteriorating
- Perfect Earnings Miss Streak↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 27, 2026· older than 90 days
TG Therapeutics, Inc. (TGTX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. At $60.75, A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source CMO/API suppliers.
TG Therapeutics is a commercial-stage biotech focused on B-cell diseases, with BRIUMVI (ublituximab-xiiy) as its sole FDA-approved product, launched in the U.S. for relapsing forms of multiple sclerosis in January 2023. Revenue comes from U.S. net product sales and ex-U.S.... Read more
Sell if holding. At $60.75, A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source CMO/API suppliers. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 5.5/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: speculative.
About TG Therapeutics, Inc.
About TG Therapeutics, Inc.
BRIUMVI (ublituximab-xiiy), TG Therapeutics' sole FDA-approved product, received clearance in December 2022 for adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company commercially launched BRIUMVI in the U.S. in January 2023 and expanded internationally through an August 2023 commercialization agreement with Neuraxpharm Pharmaceuticals, S.L. for ex-U.S. territories, with Neuraxpharm first launching BRIUMVI in Germany in February 2024. Patent protection for BRIUMVI was extended through 2042 via three USPTO patents issued in February 2024.
BRIUMVI is an anti-CD20 monoclonal antibody administered via one-hour infusion every 24 weeks. TG Therapeutics generates U.S. net product revenue from infusion-based prescriptions in the RMS market, competing against other branded anti-CD20 therapies. Ex-U.S. revenues flow through the Neuraxpharm commercialization agreement as tiered double-digit royalties on net product sales up to 30 percent plus milestone payments, with the total deal valued at up to $645 million in upfront and milestone payments. The company contracts with third parties for all commercial and clinical manufacturing — the 10-K discloses that the third parties relied upon for supply of starting materials, intermediates, active pharmaceutical ingredient (API)/drug substance, drug product, and other materials are the company's sole source of supply. Pipeline assets include subcutaneous ublituximab in a Phase 3 program that was more than approximately 75 percent enrolled in February 2026, and azer-cel (an allogeneic CD19-directed CAR T cell therapy) in a Phase 1 trial for progressive MS initiated in August 2025.
Show full overview
Manufacturing dependency exposes TG Therapeutics to meaningful supply-chain concentration. The company holds no internal manufacturing capacity; commercial BRIUMVI supply depends entirely on third-party contract manufacturers and API suppliers, each of which is the sole source for its respective materials. A disruption at any sole-source supplier could directly interrupt commercial supply, and the 10-K characterizes the loss of any such supplier as capable of significantly harming the business. The myasthenia gravis and subcutaneous ublituximab programs, if approved, would share the same sole-source supply infrastructure.
See also: Healthcare · Biotechnology
From TG Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Nov 1, 2026Recent Developments — TG Therapeutics, Inc.
Latest news
- NEWS TGTX Stock On Track For Best Day In 3.5 Months Amid Fresh Buyout Rumors - Stocktwits — Stocktwits Nov 1, 2026 positive
- NEWS TG Therapeutics, Inc. (NASDAQ: TGTX) Gains 3.01% With CCI in Overbought-Type Range - Kalkine India — Kalkine India Oct 28, 2026 positive
- NEWS Why TG Therapeutics (TGTX) Shares Climbed After Its Latest Update - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and TG Therapeutics ( — The Globe and Mail Oct 28, 2026 neutral
- NEWS TG Therapeutics (TGTX) Stock May Be Underpriced Relative To Earnings - Yahoo Finance — Yahoo Finance Oct 27, 2026 positive
Latest item Nov 1, 2026 · Generated 2026-11-04T11:54:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBRIUMVI10-K Item 1: 'TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy)'
- HIGHSuppliersole-source CMO/API suppliers10-K Item 1A: 'The third parties upon whom we rely for the supply of starting materials, intermediates, active pharmaceutical ingredient (API)/drug substance ... are our sole source of supply'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $60.75, A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source CMO/API suppliers. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $56.50. Score 5.5/10, moderate confidence.
Analyst target $60.65 reached (−0.2% from $60.75); no take-profit level is published. Prior stop was $56.50. Stop-loss: $56.50.
Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source CMO/API suppliers; Analyst target reached - limited upside remaining.
TG Therapeutics, Inc. trades at a P/E of 22.1 (forward 22.4). TrendMatrix value score: 4.5/10. Verdict: Sell.
14 analysts rate TGTX, with a consensus score of 4.0/5. 7 analysts publish price targets averaging $70.
What does TG Therapeutics, Inc. do?TG Therapeutics is a commercial-stage biotech focused on B-cell diseases, with BRIUMVI (ublituximab-xiiy) as its sole...
TG Therapeutics is a commercial-stage biotech focused on B-cell diseases, with BRIUMVI (ublituximab-xiiy) as its sole FDA-approved product, launched in the U.S. for relapsing forms of multiple sclerosis in January 2023. Revenue comes from U.S. net product sales and ex-U.S. royalties and milestones under a 2023 commercialization agreement with Neuraxpharm valued at up to $645 million.